Citations

Mayo Clinic

Showing 10 of 108602 citations.

The Neonatal Nurse Practitioner as Surgeon
Costakos, Dennis T., Dahlen, Lynn, Dunlap, Shawn , Heise, Theresa, Muellenberg, Renee, Walden, Jennifer L. , Richards, Jennifer, Walden, Jennifer

Pediatrics | March 1, 2023 | Volume: 141 | Issue: 1_MeetingAbstract | Pages: 566-566

10.1542/peds.141.1ma6.566 Get It

Computational tools for exploring peptide-membrane interactions in gram-positive bacteria
Kumar, Shreya , Balaya, Rex Devasahayam Arokia , Kanekar, Saptami , Raju, Rajesh , Prasad, Thottethodi Subrahmanya Keshava , Kandasamy, Richard K. , Prasad, Thottethodi Subrahmanya Keshav , Devasahayam Arokia Balaya, Rex

Computational and Structural Biotechnology Journal | March 1, 2023 | Volume: 21 | Issue: No issue available | Pages: 1995-2008

10.1016/j.csbj.2023.02.051 | PMID 36950221 Get It

Homeward Bound: enhanced Cross Cultural Care at End of Life Through Pediatric Palliative Transport
Brinlee, Madison A., Thorvilson, Megan J. , Manahan, Aubrey J. , Schiltz, Brenda , Collura, Christopher A.

Pediatrics | March 1, 2023 | Volume: 141 | Issue: 1_MeetingAbstract | Pages: 382-382

10.1542/peds.141.1ma4.382 Get It

Peer-designed Parents’ Bereavement Panel: Exposing First-year Medical Students to Pediatric End-of-life Care
Sunde, Kiri, Jones, Amie, Starr, Stephanie R. , Rolfes, Mary

Pediatrics | March 1, 2023 | Volume: 141 | Issue: 1_MeetingAbstract | Pages: 387-387

10.1542/peds.141.1ma4.387 Get It

Developmental Outcomes in Critically Ill Children: A Population Based Birth Cohort Report
Murphy, Sinéad, Undavalli, Chaitanya, Weaver, Amy L. , Crow, Sheri

Pediatrics | March 1, 2023 | Volume: 141 | Issue: 1_MeetingAbstract | Pages: 315-315

10.1542/peds.141.1ma4.315 Get It

Productive Pumping! Helping Trainees Increase Clinical Time
Creo, Ana L. , Anderson, Heather H., Homme, Jay H.

Pediatrics | March 1, 2023 | Volume: 141 | Issue: 1_MeetingAbstract | Pages: 295-295

10.1542/peds.141.1ma3.295 Get It

Platelet‐Rich Plasma and Marrow Venting May Serve as Cost‐Effective Augmentation Techniques for Isolated Meniscal Repair: A Decision‐Analytical Markov Model–Based Analysis
Oeding, Jacob F. , Berlinberg, Elyse J. , Marigi, Erick M. , Okoroha, Kelechi R. , Camp, Christopher L. , Barlow, Jonathan D. , Krych, Aaron J. , Camp, Christopher L. , Krych, Aaron J , Marigi, Erick , Barlow, Jonathan D , Oeding, Jacob F , Lu, Yining

Arthroscopy | March 1, 2023 | Volume: 39 | Issue: 9 | Pages: 2058-2068

10.1016/j.arthro.2023.02.018 | PMID 36868533 Get It

Purpose To evaluate the cost‐effectiveness of 3 isolated meniscal repair (IMR) treatment strategies: platelet‐rich plasma (PRP)–augmented IMR, IMR with a marrow venting procedure (MVP), and IMR without biological augmentation. Methods A Markov model was developed to evaluate the baseline case: a young adult patient meeting the indications for IMR. Health utility values, failure rates, and transition probabilities were derived from the published literature. Costs were determined based on the typical patient undergoing IMR at an outpatient surgery center. Outcome measures included costs, quality‐adjusted life‐years (QALYs), and the incremental cost‐effectiveness ratio (ICER). Results Total costs of IMR with an MVP were $8,250; PRP‐augmented IMR, $12,031; and IMR without PRP or an MVP, $13,326. PRP‐augmented IMR resulted in an additional 2.16 QALYs, whereas IMR with an MVP produced slightly fewer QALYs, at 2.13. Non‐augmented repair produced a modeled gain of 2.02 QALYs. The ICER comparing PRP‐augmented IMR versus MVP‐augmented IMR was $161,742/QALY, which fell well above the $50,000 willingness‐to‐pay threshold. Conclusions IMR with biological augmentation (MVP or PRP) resulted in a higher number of QALYs and lower costs than non‐augmented IMR, suggesting that biological augmentation is cost‐effective. Total costs of IMR with an MVP were significantly lower than those of PRP‐augmented IMR, whereas the number of additional QALYs produced by PRP‐augmented IMR was only slightly higher than that produced by IMR with an MVP. As a result, neither treatment dominated over the other. However, because the ICER of PRP‐augmented IMR fell well above the $50,000 willingness‐to‐pay threshold, IMR with an MVP was determined to be the overall cost‐effective treatment strategy in the setting of young adult patients with isolated meniscal tears. Level of Evidence Level III, economic and decision analysis.
A Primary Care-ent Initiative to Improve Value for Children with Middle Ear Disease
Mattke, Angela, Wong-Nano, Gisella, Martin, Valérie, Cofer, Shelagh A. , Wi, Chung I., Cook, Walter J., Juhn, Young J. , Soma, David , Homme, Jason H. , Starr, Stephanie R. , Martin, Valerie, Wi, Chung‐Il

Pediatrics | March 1, 2023 | Volume: 141 | Issue: 1_MeetingAbstract | Pages: 83-83

10.1542/peds.141.1ma1.83 Get It

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
Aaroe, Ashley , Goyal, Gaurav , Goodman, Aaron M. , Patel, Harsh , Ruan, Gordon , Ulaner, Gary A. , Li, Ziyi , Dustin, Derek , Janku, Filip, Goyal, Guarav , Ruan, Gordon J , Ulaner, Gary , Li, Ziyi , Diamond, Eli L , Kurzrock, Razelle , Patel, Harsh, Young, Jason , Go, Ronald S. , Diamond, Eli L.

Blood Advances | March 1, 2023 | Volume: 7 | Issue: 15 | Pages: 3984-3992

10.1182/bloodadvances.2022009013 | PMID 36857436 Get It

Abstract Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) are rare non-Langerhans cell histiocytoses (non-LCHs), for which therapeutic options are limited. MAPK pathway activation through BRAFV600E mutation or other genomic alterations is a histiocytosis hallmark and correlates with a favorable response to BRAF inhibitors and the MEK inhibitor cobimetinib. However, there has been no systematic evaluation of alternative MEK inhibitors. To assess the efficacy and safety of the MEK inhibitor trametinib, we retrospectively analyzed the outcomes of 26 adult patients (17 with ECD, 5 with ECD/RDD, 3 with RDD, and 1 with ECD/LCH) treated with orally administered trametinib at 4 major US care centers. The most common treatment-related toxicity was rash (27% of patients). In most patients, the disease was effectively managed at low doses (0.5-1.0 mg trametinib daily). The response rate of the 17 evaluable patients was 71% (73% [8/11] without a detectable BRAFV600E achieving response). At a median follow-up of 23 months, treatment effects were durable, with a median time-to-treatment failure of 37 months, whereas the median progression-free and overall survival were not reached (at 3 years, 90.1% of patients were alive). Most patients harbored mutations in BRAF (either classic BRAFV600E or other BRAF alterations) or alterations in other genes involved in the MAPK pathway, eg, MAP2K, NF1, GNAS, or RAS. Most patients required lower than standard doses of trametinib but were responsive to lower doses. Our data suggest that the MEK inhibitor trametinib is an effective treatment for ECD and RDD, including those without the BRAFV600E mutation.
Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
Waller, Rosalie G. , Hanson, Heidi A. , Avery, Brian J. , Madsen, Michael J. , Sborov, Douglas W. , Camp, Nicola J. , Griffin, R. L. , Waller, Rosalie G , Griffin, Rosalie

Cancer Epidemiology, Biomarkers & Prevention | March 1, 2023 | Volume: 32 | Issue: 5 | Pages: 708-717

10.1158/1055-9965.epi-22-0798 | PMID 36857768 Get It

Abstract Background: Transcriptome studies are gaining momentum in genomic epidemiology, and the need to incorporate these data in multivariable models alongside other risk factors brings demands for new approaches. Methods: Here we describe SPECTRA, an approach to derive quantitative variables that capture the intrinsic variation in gene expression of a tissue type. We applied the SPECTRA approach to bulk RNA sequencing from malignant cells (CD138+) in patients from the Multiple Myeloma Research Foundation CoMMpass study. Results: A set of 39 spectra variables were derived to represent multiple myeloma cells. We used these variables in predictive modeling to determine spectra-based risk scores for overall survival, progression-free survival, and time to treatment failure. Risk scores added predictive value beyond known clinical and expression risk factors and replicated in an external dataset. Spectrum variable S5, a significant predictor for all three outcomes, showed pre-ranked gene set enrichment for the unfolded protein response, a mechanism targeted by proteasome inhibitors which are a common first line agent in multiple myeloma treatment. We further used the 39 spectra variables in descriptive modeling, with significant associations found with tumor cytogenetics, race, gender, and age at diagnosis; factors known to influence multiple myeloma incidence or progression. Conclusions: Quantitative variables from the SPECTRA approach can predict clinical outcomes in multiple myeloma and provide a new avenue for insight into tumor differences by demographic groups. Impact: The SPECTRA approach provides a set of quantitative phenotypes that deeply profile a tissue and allows for more comprehensive modeling of gene expression with other risk factors.